Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Neoplasms 14Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 2Mesothelioma 2Melanoma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

Nivolumab 2Ipilimumab 2Cisplatin 2tocilizumab 1budigalimab 1belinostat 1Topotecan 1Specimen Handling 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Irinotecan 1Etoposide 1Carboplatin 1Biopsy 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Neuroendocrine × budigalimab × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡